Physician profile
John W Patton
NPI 1508030313
$28,891.99
in general payments reported to CMS, 2019-2025
45 companies · $2,438 in 2025
The $2,438 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,596 · 2020: $7,908 · 2021: $5,448 · 2022: $1,817 · 2023: $2,110 · 2024: $2,576 · 2025: $2,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,123.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15,475.65 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $2,423.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,444.86 | 2019-2025 | Farxiga, Wainua, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $1,200.77 | 2019-2025 | Camzyos, Eliquis, Empliciti |
| Janssen Pharmaceuticals, INC | $1,135.78 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,035.81 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $829.09 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $723.69 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $698.33 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.84 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $423.82 | 2019-2025 | Watchman Flx, Cds - Mct/Cem Monitoring, Watchman Access System |
| Chiesi USA, INC. | $377.06 | 2019-2025 | Kengreal, Cleviprex |
| Novo Nordisk INC | $323.19 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $234.94 | 2024-2025 | Pressurewire, Diamondback Coronary, Xience Skypoint |
| Sanofi-Aventis U.S. LLC | $218.32 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.